Blog

Has the FDA’s ruling on direct-to-consumer genetic testing given power to the people?

The US Food and Drug Administration announced on 6 April, 2017 that it has “allowed marketing of 23andMe Personal Genome Service Genetic Health Risk (GHR) tests for 10 diseases or conditions. These are the first direct-to-consumer (DTC) tests authorized by the FDA that provide information on an individual’s genetic predisposition to certain medical diseases or […]

Which pharma companies are ready for diagnostic integration in 2017?

The regular Pharma Readiness reports produced by Diaceutics aim to capture a snapshot of the diagnostic and precision medicine industries at certain times in a fast-evolving landscape. Pharma Readiness for Diagnostic Integration 2017 is no exception and discusses such vital topics as: Trends, best practice and preferred organizational styles in diagnostics (Dx) and precision medicine […]

What can pharma do to get ahead of their PM competitors?

In the article Immuno-Oncology Drug Rivalries Highlight Biomarkers Opportunities, Challenges published in The MedTech Strategist (March 2017), the rivalries between big pharma and their biomarkers are highlighted. The battle between Merck and BMS around their Keytruda and Opdivo therapies in particular could mark “a potential turning point for the molecular diagnostics industry, which has since […]

How can real-time analysis of the PD-L1 testing market boost precision medicine?

In an article for Clinical Lab Products magazine, The Evolution of the PD-L1 Testing Market, Peter Keeling and Ewelina Golebiewska examine how the extraordinarily dynamic PD-L1 space is providing opportunities to undertake real-time market analysis and ultimately improve our understanding of novel biomarker adoption. This active approach to real-time analysis, combined with the insights of […]

Why is there such a difference in European PD-L1 test adoption?

Implementation of biomarker testing is key to the success of precision medicine. The success of therapies based on immuno-oncology, with over six indications in recent years (predominantly lung cancer), has highlighted the need for PD-L1 biomarker testing and the challenges it raises for implementation. In our February 2017 webinar we discuss the adoption of PD-L1 […]